Kalvista Begin Period Cash Flow vs Net Income Analysis

KALV Stock

USD 8.36 0.27 3.34%

Kalvista Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kalvista Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kalvista Pharmaceuticals is a good investment. Please check the relationship between Kalvista Pharmaceuticals Begin Period Cash Flow and its Net Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

Begin Period Cash Flow vs Net Income

Begin Period Cash Flow vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kalvista Pharmaceuticals Begin Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Kalvista Pharmaceuticals' Begin Period Cash Flow and Net Income is -0.71. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of Kalvista Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kalvista Pharmaceuticals' Begin Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Kalvista Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Begin Period Cash Flow i.e., Kalvista Pharmaceuticals' Begin Period Cash Flow and Net Income go up and down completely randomly.

Correlation Coefficient

-0.71

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Kalvista Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Kalvista Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Kalvista Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kalvista Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.Enterprise Value is likely to climb to about 131.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.9 M in 2024.

	2023	2024 (projected)
Net Interest Income	3.9M	4.1M
Non Recurring	1.3M	1.2M

Net Interest Income Non Recurring

Kalvista Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Assets	Long Term Debt
Total Assets		0.57	0.9	0.6	0.99	0.81	0.42	-0.62	-0.82	0.75	0.54	0.79	-0.18	1.0	0.81	0.71	-0.62	0.76	0.93	-0.21	0.92	1.0	-0.52	0.8	-0.32	0.37
Short Long Term Debt Total	0.57		0.51	0.13	0.56	0.68	-0.18	-0.03	-0.67	0.54	0.22	0.71	0.36	0.56	0.53	0.48	0.0	0.5	0.59	-0.13	0.69	0.55	0.26	0.55	0.23	0.47
Other Current Liab	0.9	0.51		0.74	0.88	0.71	0.42	-0.53	-0.94	0.91	0.4	0.7	-0.15	0.88	0.78	0.67	-0.59	0.72	0.97	-0.14	0.94	0.89	-0.48	0.8	-0.31	0.35
Total Current Liabilities	0.6	0.13	0.74		0.56	0.45	0.56	-0.64	-0.65	0.72	0.43	0.45	-0.11	0.58	0.49	0.52	-0.43	0.47	0.67	0.12	0.63	0.59	-0.5	0.53	-0.22	-0.05
Total Stockholder Equity	0.99	0.56	0.88	0.56		0.81	0.46	-0.62	-0.8	0.74	0.57	0.8	-0.11	0.99	0.84	0.73	-0.68	0.76	0.91	-0.34	0.89	0.99	-0.55	0.82	-0.24	0.34
Property Plant And Equipment Net	0.81	0.68	0.71	0.45	0.81		0.43	-0.54	-0.79	0.7	0.58	0.99	-0.04	0.79	0.78	0.93	-0.5	0.72	0.79	-0.24	0.84	0.8	-0.39	0.82	-0.14	0.24
Current Deferred Revenue	0.42	-0.18	0.42	0.56	0.46	0.43		-0.79	-0.34	0.37	0.58	0.41	-0.26	0.41	0.42	0.55	-0.71	0.36	0.42	-0.38	0.35	0.43	-0.82	0.44	-0.27	-0.59
Net Debt	-0.62	-0.03	-0.53	-0.64	-0.62	-0.54	-0.79		0.43	-0.39	-0.84	-0.5	0.33	-0.62	-0.65	-0.52	0.71	-0.35	-0.53	0.21	-0.49	-0.62	0.8	-0.57	0.35	0.27
Retained Earnings	-0.82	-0.67	-0.94	-0.65	-0.8	-0.79	-0.34	0.43		-0.96	-0.38	-0.78	0.08	-0.81	-0.76	-0.74	0.46	-0.66	-0.95	0.06	-0.96	-0.82	0.32	-0.84	0.27	-0.32
Accounts Payable	0.75	0.54	0.91	0.72	0.74	0.7	0.37	-0.39	-0.96		0.36	0.7	0.01	0.75	0.71	0.73	-0.48	0.58	0.89	-0.08	0.88	0.75	-0.35	0.83	-0.2	0.24
Cash	0.54	0.22	0.4	0.43	0.57	0.58	0.58	-0.84	-0.38	0.36		0.54	0.01	0.55	0.78	0.57	-0.75	0.26	0.38	-0.42	0.4	0.54	-0.66	0.73	0.0	-0.16
Non Current Assets Total	0.79	0.71	0.7	0.45	0.8	0.99	0.41	-0.5	-0.78	0.7	0.54		0.05	0.77	0.75	0.93	-0.46	0.7	0.77	-0.27	0.83	0.78	-0.32	0.81	-0.05	0.23
Non Currrent Assets Other	-0.18	0.36	-0.15	-0.11	-0.11	-0.04	-0.26	0.33	0.08	0.01	0.01	0.05		-0.17	-0.03	0.01	0.2	-0.2	-0.22	-0.46	-0.17	-0.19	0.48	0.06	0.96	-0.05
Cash And Short Term Investments	1.0	0.56	0.88	0.58	0.99	0.79	0.41	-0.62	-0.81	0.75	0.55	0.77	-0.17		0.8	0.7	-0.61	0.71	0.91	-0.2	0.9	1.0	-0.5	0.79	-0.31	0.36
Common Stock Total Equity	0.81	0.53	0.78	0.49	0.84	0.78	0.42	-0.65	-0.76	0.71	0.78	0.75	-0.03	0.8		0.72	-0.82	0.65	0.75	-0.45	0.78	0.81	-0.62	0.95	-0.11	0.31
Common Stock Shares Outstanding	0.71	0.48	0.67	0.52	0.73	0.93	0.55	-0.52	-0.74	0.73	0.57	0.93	0.01	0.7	0.72		-0.57	0.59	0.71	-0.28	0.73	0.71	-0.48	0.84	-0.11	0.1
Non Current Liabilities Total	-0.62	0.0	-0.59	-0.43	-0.68	-0.5	-0.71	0.71	0.46	-0.48	-0.75	-0.46	0.2	-0.61	-0.82	-0.57		-0.52	-0.53	0.6	-0.49	-0.62	0.92	-0.76	0.22	0.04
Other Current Assets	0.76	0.5	0.72	0.47	0.76	0.72	0.36	-0.35	-0.66	0.58	0.26	0.7	-0.2	0.71	0.65	0.59	-0.52		0.75	-0.22	0.79	0.75	-0.45	0.58	-0.23	0.36
Other Stockholder Equity	0.93	0.59	0.97	0.67	0.91	0.79	0.42	-0.53	-0.95	0.89	0.38	0.77	-0.22	0.91	0.75	0.71	-0.53	0.75		-0.08	0.98	0.93	-0.44	0.78	-0.39	0.34
Total Liab	-0.21	-0.13	-0.14	0.12	-0.34	-0.24	-0.38	0.21	0.06	-0.08	-0.42	-0.27	-0.46	-0.2	-0.45	-0.28	0.6	-0.22	-0.08		-0.06	-0.21	0.35	-0.39	-0.49	0.14
Property Plant And Equipment Gross	0.92	0.69	0.94	0.63	0.89	0.84	0.35	-0.49	-0.96	0.88	0.4	0.83	-0.17	0.9	0.78	0.73	-0.49	0.79	0.98	-0.06		0.91	-0.37	0.8	-0.33	0.39
Total Current Assets	1.0	0.55	0.89	0.59	0.99	0.8	0.43	-0.62	-0.82	0.75	0.54	0.78	-0.19	1.0	0.81	0.71	-0.62	0.75	0.93	-0.21	0.91		-0.53	0.8	-0.32	0.37
Short Term Debt	-0.52	0.26	-0.48	-0.5	-0.55	-0.39	-0.82	0.8	0.32	-0.35	-0.66	-0.32	0.48	-0.5	-0.62	-0.48	0.92	-0.45	-0.44	0.35	-0.37	-0.53		-0.55	0.46	0.2
Common Stock	0.8	0.55	0.8	0.53	0.82	0.82	0.44	-0.57	-0.84	0.83	0.73	0.81	0.06	0.79	0.95	0.84	-0.76	0.58	0.78	-0.39	0.8	0.8	-0.55		-0.08	0.26
Other Assets	-0.32	0.23	-0.31	-0.22	-0.24	-0.14	-0.27	0.35	0.27	-0.2	0.0	-0.05	0.96	-0.31	-0.11	-0.11	0.22	-0.23	-0.39	-0.49	-0.33	-0.32	0.46	-0.08		-0.1
Long Term Debt	0.37	0.47	0.35	-0.05	0.34	0.24	-0.59	0.27	-0.32	0.24	-0.16	0.23	-0.05	0.36	0.31	0.1	0.04	0.36	0.34	0.14	0.39	0.37	0.2	0.26	-0.1

Click cells to compare fundamentals

Kalvista Pharmaceuticals Account Relationship Matchups

Kalvista Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	118.1M	92.5M	272.0M	203.9M	183.2M	235.4M
Short Long Term Debt Total	54K	1.6M	5.9M	8.2M	8.2M	7.3M
Other Current Liab	5.5M	6.9M	7.0M	9.1M	12.4M	29K
Total Current Liabilities	18.1M	7.7M	9.8M	11.6M	15.0M	22.8M
Total Stockholder Equity	96.7M	83.8M	257.2M	185.1M	161.0M	206.6M
Property Plant And Equipment Net	3.7M	7.5M	10.0M	10.8M	9.1M	9.6M
Net Debt	(14.1M)	(44.7M)	(22.5M)	(48.0M)	(24.5M)	(25.7M)
Retained Earnings	(92.5M)	(121.6M)	(167.8M)	(250.2M)	(343.1M)	(469.7M)
Accounts Payable	2.9M	1.7M	2.0M	3.6M	4.8M	9.1M
Cash	32.0M	15.8M	50.6M	30.7M	56.2M	31.8M
Non Current Assets Total	3.8M	7.7M	10.2M	10.9M	9.7M	10.2M
Cash And Short Term Investments	100.8M	67.7M	248.9M	166.2M	149.4M	210.4M
Common Stock Total Equity	17K	18K	24K	25K	34K	18.2K
Common Stock Shares Outstanding	17.7M	19.1M	24.5M	27.9M	36.8M	38.6M
Liabilities And Stockholders Equity	92.5M	272.0M	203.9M	183.2M	235.4M	247.2M
Non Current Liabilities Total	1.1M	5.0M	7.2M	7.1M	6.0M	10.7M
Other Current Assets	4.5M	3.6M	10.6M	4.3M	4.4M	1.0M
Other Stockholder Equity	207.2M	426.4M	439.1M	507.1M	679.8M	(75K)
Total Liab	21.4M	8.8M	14.8M	18.8M	22.2M	28.8M
Property Plant And Equipment Gross	2.4M	3.7M	7.5M	10.0M	10.8M	12.9M
Total Current Assets	115.5M	88.7M	264.3M	193.6M	172.3M	225.7M
Accumulated Other Comprehensive Income	(1.9M)	(1.9M)	(1.4M)	(3.9M)	(3.1M)	(3.5M)
Short Term Debt	54K	588K	863K	977K	1.1M	1.3M
Common Stock	17K	18K	24K	25K	34K	42K
Capital Surpluse	191.1M	207.2M	426.4M	439.1M	507.1M	115.8M
Property Plant Equipment	2.4M	2.0M	1.8M	2.2M	2.9M	1.3M
Net Tangible Assets	83.8M	257.2M	185.1M	161.0M	43.1M	40.9M
Net Receivables	11.3M	16.5M	10.4M	14.1M	16.6M	10.9M
Retained Earnings Total Equity	(71.7M)	(92.5M)	(121.6M)	(167.8M)	(250.2M)	(343.1M)
Short Term Investments	68.8M	51.9M	198.3M	135.5M	93.1M	178.6M
Net Invested Capital	83.8M	257.2M	185.1M	161.0M	206.6M	144.2M
Net Working Capital	81.0M	254.5M	182.1M	157.3M	202.9M	143.4M
Capital Lease Obligations	1.6M	5.9M	8.2M	8.2M	7.3M	4.9M
Capital Stock	18K	24K	25K	34K	42K	29.3K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC